C07K 14/045
Cytomegalovirus
C07K14/045 (Cytomegalovirus) appears on 33 US grants and 43 published applications in this corpus.
Search patents in C07K- Granted patents
- 33
- Published applications
- 43
- Assignees
- 23
- Inventors
- 61
- Latest grant
- 21 Oct 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 1 | 1 |
| 2012 | 1 | 1 |
| 2013 | 0 | 4 |
| 2014 | 4 | 2 |
| 2015 | 1 | 2 |
| 2016 | 4 | 4 |
| 2017 | 1 | 1 |
| 2018 | 1 | 1 |
| 2019 | 3 | 3 |
| 2020 | 1 | 4 |
| 2021 | 3 | 3 |
| 2022 | 4 | 4 |
| 2023 | 3 | 3 |
| 2024 | 3 | 5 |
| 2025 | 2 | 1 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Human cytomegalovirus gB polypeptide21 Oct 2025US 12,447,207 B2Pfizer Inc.
- Modified cytomegalovirus proteins and stabilized complexes12 Aug 2025US 12,384,819 B2Glaxosmithkline Biologicals SA
- Clinical methods for use of a PD-L1-binding molecule comprising a Shiga toxin effector31 Dec 2024US 12,180,284 B2Molecular Templates, Inc.
- Modified cytomegalovirus proteins and stabilized complexes19 Mar 2024US 11,932,669 B2Glaxosmithkline Biologicals SA
- Human cytomegalovirus GB polypeptide2 Jan 2024US 11,857,622 B2Pfizer Inc.
- Modified cytomegalovirus proteins and stabilized complexes27 Aug 2026US 2026/0250330 A1Glaxosmithkline Biologicals SA
- Human cytomegalovirus gb polypeptide20 Aug 2026US 2026/0240988 A1Pfizer Inc.
- Therapeutic and diagnostic agents and uses thereof25 Sep 2025US 2025/0296984 A1Thelper AS
- Modified cytomegalovirus proteins and stabilized complexes21 Nov 2024US 2024/0383949 A1Glaxosmithkline Biologicals SA
- Therapeutic and diagnostic agents and uses thereof20 Jun 2024US 2024/0199724 A1
Most cited
By later US patents
- Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection27US 7,410,795 B2Vical Incorporated · 2008
- Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection23US 7,888,112 B2Vical Incorporated · 2011
- Recombinant HCMV and RHCMV vectors and uses thereof20US 9,249,427 B2Oregon Health & Science University · 2016
- Codon-optimized polynucleotide-based vaccines against human Cytomegalovirus infection16US 8,673,317 B2Vical Incorporated · 2014
- Recombinant HCMV and RHCMV vectors and uses thereof13US 9,982,241 B2Oregon Health & Science University · 2018